Baltimore, Maryland 21201

  • Cervical Intraepithelial Neoplasia


The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.

Study summary:

This was an open-label, pilot Phase I/II dose evaluation and pharmacokinetic evaluation study to compare the safety and efficacy of terameprocol (45mg or 90mg/application)administered once per week for 3 weeks to the cervix uteri in patients with biopsy-proven CIN. Patients who met eligibility criteria visited the clinic weekly for terameprocol application. Patients kept a daily diary card record of genitourinary symptoms.


Inclusion Criteria: - 18 years of age or older - Negative pregnancy test - Biopsy confirmed CIN 1, 2, or 3 Exclusion Criteria: - Pregnancy or breast feeding



Primary Contact:


Backup Contact:


Location Contact:

Baltimore, Maryland 21201
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.